Finding new cancer markers for T-cell immunotherapy
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11122351
This work looks for new ways to identify unique markers on cancer cells that our immune system's T-cells can recognize and attack, especially for melanoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11122351 on ClinicalTrials.gov |
What this research studies
Immunotherapy using T-cells has shown great promise in treating various cancers by training these cells to find and destroy tumor cells. T-cells identify cancer cells by recognizing specific markers, called antigens, on their surface. Currently, we can only find a few of these important markers using standard methods. This project aims to discover 'unconventional' markers that come from unexpected parts of cancer cells, which could significantly expand the number of targets for T-cell therapies. By finding these new targets, we hope to create more effective personalized vaccines and T-cell treatments for patients.
Who could benefit from this research
Good fit: This foundational research is relevant for patients with melanoma and other cancers that could benefit from T-cell based immunotherapies.
Not a fit: Patients whose cancer does not present these specific types of unconventional antigens or who are not candidates for T-cell immunotherapy may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new and more effective personalized immunotherapies for cancer patients, particularly those with melanoma.
How similar studies have performed: T-cell based immunotherapies have already shown significant success in treating several cancer types, but this approach focuses on identifying novel, unconventional targets.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIZEE, GREGORY A — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LIZEE, GREGORY A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.